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Abstract
Background: Methadone maintenance treatment (MMT) might be associated with the symptoms of depression
and anxiety, sleep disturbances and sexual dysfunctions. This study was designed to determine the effects of crocin
on psychological parameters in patients under MMT.
Methods: Patients under MMT were randomly allocated into two groups to receive either 30 mg/day crocin (2 plus
crocin tablet, 15 mg BID) (n = 25) or placebo (2 tablets per day, 15 mg BID) (n = 25), one hour after taking food, for
8 weeks. Psychological parameters were evaluated at baseline and end of the trial to determine related associations
between crocin and patients’ mental health status.
Results: After 8-week intervention, crocin significantly decreased Beck Depression Inventory (b − 6.66; 95% CI, − 9.88, −
3.45; P < 0.0001), Beck Anxiety Inventory (b − 4.35; 95% CI, − 5.94, − 2.75; P < 0.0001), general health questionnaire (b − 4.
45; 95% CI, − 7.68, − 1.22; P = 0.008) and Pittsburgh Sleep Quality Index (b − 2.73; 95% CI, − 3.74, − 1.73; P < 0.0001) in
patients under MMT, compared with the placebo. Crocin also significantly improved International Index of Erectile
Functions (b 4.98; 95% CI, 2.08, 7.88; P = 0.001) rather than placebo.
Conclusion: Our findings indicated that taking crocin for 8 weeks by patients under MMT had beneficial effects on
their mental health status. Crocin can be recommended as an adjunct to methadone in opioid withdrawal protocols
because of the ability to improve the quality of life and decrease opioids side effects in these patients.
This trial was registered in the Iranian website for clinical trials registry as http://www.irct.ir: IRCT2017110537243N1.
Clinical trial registration number: www.irct.ir: http://www.irct.ir: IRCT2017110537243N1.
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Background
Methadone is well-known for treating opioids depend-
ence and managing chronic pain among patients suffer-
ing from withdrawal syndrome [1]. Being the most
cost-effective treatment for opioid dependence, interest
in adding it to opioid withdrawal protocols [2, 3] is
growing. Methadone maintenance treatment (MMT)
might improve social functioning and quality of life
among patients with chronic dependence [4]. However,
despite the practical implementation of MMT, many
challenges and hurdles remained unsolved. There are
evidence demonstrating the association between sub-
stance dependence and comorbid conditions, specifically
psychological syndromes [5]. However, MMT also might
be associated with depression and anxiety [6], sleep dis-
turbances [7] and sexual dysfunctions [8] among patients
suffering from withdrawal syndrome.
Crocus sativus L., commonly known as saffron, belongs
to iridaceous family [9]. Several crops are available in
France, New Zealand, Switzerland, the United States,
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England, and other countries some of them organically
grown. In the United States, Pennsylvania Dutch saffron
known for its “earthy” notes is marketed in small quan-
tities [10]. Saffron contains several compounds such as
safranal, picrocrocin and crocin, the latter is the main
antioxidant in saffron working as a dye [11]. Saffron and
mainly crocin are effective antidepressant and anti-
anxiety agents [12], as well as sexual motivator [13],
memory enhancer and sedative which are used for the
treatment of different central nervous system disorders
[14]. The beneficial effects of crocin on psychological pa-
rameters have been shown in patients not taking MMT.
Talaei et al. [12] have documented that consuming 30
mg/day crocin for 4 weeks significantly improved mental
health parameters including depression, anxiety, general
health, and mood disorders in patients suffering from
major depressive disorder (MDD). Current evidence
demonstrating that saffron administration, at a dosage of
28 mg/day for 4 weeks, had beneficial effects on mood,
anxiety, and stress management in individuals self-
reporting low mood, yet sleep quality did not improve
[15]. Recent studies have shown that daily oral con-
sumption of saffron capsules improves sleep quality in
diabetic patients [16], and sexual dysfunction among
women [13].
Saffron and crocin may improve the function of cen-
tral nervous system and mental health status through
regulating the synthesis of chemical neurotransmitters
in the brain, including dopamine, norepinephrine, and
serotonin (5- hydroxyltryptamine) [17–19]. To our best
knowledge, evidence demonstrating the effects of cro-
cin on improving psychological symptoms in patients
under MMT are scarce. So, in the present placebo-
controlled clinical trial, we aimed to determine the ef-
fects of crocin on psychological symptoms in patients
undergoing MMT.
Methods
Preparation of crocin tablets
Saffron stigmas were purchased from Novin Saffron
Co. (Mashhad, Iran). Crocin was extracted and crystal-
lized from saffron stigmas, using a previous published
protocol [20]. Crocin and placebo were similarly formu-
lated into film-coated tablets by the Department of
Pharmaceutics, School of Pharmacy in Mashhad Uni-
versity of Medical Science. Each tablet contained 15 mg
crocin or placebo.
Study design and participants
This randomized, double-blinded, placebo-controlled
trial (RCT) was registered in the Iranian website for clin-
ical trials registry (http://www.irct.ir: IRCT2017110
537243N1 (one of the Primary Registries in WHO Regis-
try Network, with the collaboration of both Ministry of
Health and Medical Education. This trial was conducted
following Declaration of Helsinki; informed consent was
signed by all participants prior to intervention. The
subjects were recruited in the Referral center (the
Golabchi Clinic) for patients under MMT subjects in
Kashan-Iran within a month starting from November 1,
2017. Then, 50 patients, aged 18–60 years, taking MMT
were intervened for two months, starting from Decem-
ber 5, 2017. All patients were examined by a psychiatrist
according to the fourth revision of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV). Indi-
viduals with the following criteria were included in the
trial: confirmed diagnosis of substance dependency
based on DSM-IV, the age range of 18–60 years, pa-
tients’ willingness to participate in the intervention. The
main exclusion criteria were as followed: taking crocin,
multivitamin-mineral and antioxidant supplements dur-
ing the last 3 months before the intervention initiation,
history of metabolic diseases including diabetes, hyper-
tension, thyroid and cardiovascular disease.
Study protocol
Patients under MMT were randomly allocated into two
groups to receive either 30 mg/day crocin (2 plus crocin
tablet, 15 mg BID) (n = 25) or placebo (2 tablets per day,
15 mg BID) (n = 25), one hour after taking food, for 8
weeks. Due to lack of evidence about the appropriate
dosage of crocin usage in cases under MMT, we used
the above-mentioned dose of crocin based on a previous
published study in subjects with major depressive
disorder (MDD) [12]. A trained staff randomized the
subjects using computer-generated random numbers, at
the clinic. Randomization and allocation were concealed
to the researchers and participants until the completion
of final analyses. The crocin and the placebo tablets were
prepared in the same shape, color, size, texture and odor,
and each tablet container had a random code number
for this double-blinded trial. The tablets were ordered to
College of Pharmacy, Mashhad University of Medical
Sciences. Thus, participants, physician and other investi-
gators were all blind to the treatment group assignment.
Study participants were instructed to have their regu-
lar physical activity and not taking any additional
supplements during the 8-week intervention. The com-
pliance rate was monitored by sending a brief daily
reminder to the participants’ cellphone to take the sup-
plement and counting the left tablets in returned con-
tainers. All participants completed a 3-day food record
and a physical activity form prior to intervention, at
weeks 2, 4 and 6 and end of the trial. Daily macro- and
micro-nutrient intakes were calculated by analyzing food
data using nutritionist IV software (First Databank, San
Bruno, CA). In this trial, physical activity was indicated
as metabolic equivalents (METs) in hours per day [21].
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Safety
Participants were asked about any adverse events or
complaint during the trial. The symptoms were checked
and recorded at baseline and each follow-up visit. Prob-
able side effects were checked and recorded via every
day follow-up call and the psychiatrists and physician in
charge were responsible for continuing or discontinuing
the intervention.
Measurements
Anthropometric measures
Participants’ weight and height were measured, after an
overnight fasting, using a standard calibrated scale (Seca,
Hamburg, Germany) at baseline and end of the interven-
tion. Body Mass Index (BMI) was calculated as weight in
kg divided by height in meters squared.
Clinical measures
Psychological outcomes were assessed using Beck De-
pression Inventory − 21 (BDI-21), General Health Ques-
tionnaire − 28 (GHQ-28), Beck Anxiety Inventory − 21
(BAI-21), The Pittsburgh Sleep Quality Index (PSQI)
and Internal Index for Erectile Function (IIEF-15). Beck
Depression Inventory is the reliable and valid scale of
self-rating depression which is commonly used in clin-
ical settings. It consists of 21 items including emotional,
behavioral, and somatic symptoms. Beck Depression In-
ventory scores between 0 and 9, 10–19, and 20–29
stands for normal, mild, and moderate depression re-
spectively. While, the score of 30 and over is indicative
of major depression [22]. General Health Questionnaire
is a screening device, suitable for all ages except chil-
dren, which is used to detect minor psychiatric disor-
ders. It consists of 28 items for the diagnosis of somatic
symptoms, anxiety and insomnia, social dysfunction, and
severe depression; total score ranges from 28 to 112 [23]
with higher scores representing the poorer psychological
condition of patients. Beck Anxiety Inventory is a brief
measure of anxiety with a focus on its somatic symp-
toms. It consists of 21 items, describing emotional,
physiological, and cognitive symptoms of anxiety, which
measures the severity of anxiety in adults and adoles-
cents. The scores of 0–21, 22–35, and 35–63 indicate
mild, moderate, and severe anxiety respectively [24]. The
Internal Index for Erectile Function (IIEF) evaluates
men’s sexual function. It consists of 15 questions in five
dimensions of sexual desire, orgasm, erection, sexual sat-
isfaction, and overall satisfaction. The total score ranges
between 0 and 75; the higher the score the better the
sexual functioning. Scores of 0–10, 11–16, 17–21, and
22–25 are indicative of severe, average, average to mild,
and mild sexual dysfunction; scores of 26–30 indicate
normal sexual function [25]. The Pittsburgh Sleep Qual-
ity Index (PSQI) is an applicable instrument used to
measure the quality and pattern of sleep in adults. It dif-
ferentiates “poor” from “good” sleep quality by measur-
ing seven components of sleep including: subjective
sleep quality, sleep latency, sleep duration, habitual sleep
efficiency, sleep disturbances, use of sleeping medica-
tions, and daytime dysfunction over the last month [26].
Sample size
We used RCTs sample size formula, with type one (α)
error to be 0.05 and the power 80%, to calculate sample
size. Based on a previous study [12], a standard deviation
(SD) of 6.1 and a difference in mean (d) of 11.45 were
used considering BDI as the key variable. Based on a
previous study, using formula for clinical trial sample
size calculation, 25 individuals should have been enrolled
in each group. Assuming a dropout of 20% individuals
per group, the final sample size was considered to be 30
participants in each intervention group.
Statistical analysis
The Kolmogorov-Smirnov test was done to determine
the normality of data. To detect the differences in an-
thropometric measures, nutrient intakes and psycho-
logical parameters between treatment groups, we used
independent-samples t-test. Multiple linear regression
models were applied to determine treatment effects on
study outcomes after adjusting for confounding parame-
ters including; age, and BMI. The effect sizes were pre-
sented as the mean differences with 95% confidence
intervals. Differences in proportions were evaluated by
Chi square test. P-values < 0.05 were considered statisti-
cally significant. All statistical analyses were done using
the Statistical Package for Social Science version 18
(SPSS Inc., Chicago, Illinois, USA).
Results
Five patients from each intervention group withdraw
from the trial due to personal reasons. Finally, 50 partici-
pants [crocin (n = 25) and placebo (n = 25)] completed
the study (Fig. 1). The compliance rate in this study was
high; more than 90% of capsules were taken throughout
the intervention in both groups. No serious side effects
were reported following the consumption of crocin.
However, grade 1 side effects were reported in 6 patients
using crocin [headache (n = 2), insomnia (n = 1), nausea
(n = 2) and dyspnea (n = 1)] and 2 patients in the placebo
group [headache (n = 1) and nausea (n = 1)], which did
not lead to excluding any patients from the study.
Education level, marital status, job, other medication
consumption, methadone dose, the duration of MMT
and mean age, height, weight and BMI were not signifi-
cantly different between crocin and placebo groups
(Table 1).
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Macro- and micro-nutrient intakes, calculated based
on 3-days food records, were not significantly different
between intervention groups (Data not shown).
Crocin significantly decreased BDI (b − 6.66; 95% CI, −
9.88, − 3.45; P < 0.0001), BAI (b − 4.35; 95% CI, − 5.94, −
2.75; P < 0.0001), GHQ (b − 4.45; 95% CI, − 7.68, − 1.22;
P = 0.008) and PSQI (b − 2.73; 95% CI, − 3.74, − 1.73; P <
0.0001) in patients undergoing MMT, compared with the
placebo. In addition, crocin significantly improved IIEF in
these patients (b 4.98; 95% CI, 2.08, 7.88; P = 0.001) com-
pared with the placebo (Table 2). Changes in BDI score,
BAI score, GHQ score, PSQI score and IIEF score in pa-
tients under MMT receiving crocin supplements and pla-
cebo are presented in Figs. 2 & 3.
Discussion
We evaluated the impacts of 8 weeks crocin intake on
psychological parameters in patients under MMT. Our
findings documents that crocin in patients under MMT
significantly improves their depression, anxiety, general
health, sleep quality and erectile functions. Based on
these findings, crocin may be recommended as an
adjunct therapy for opioid-dependent patients under
treatment with MMT. To our best knowledge, this study
for the first evaluated the effects of crocin on psycho-
logical symptoms of patients undergoing MMT.
Effects on depression, anxiety and general health
Methadone maintenance treatment is usually associated
with some complications including depression, anxiety
and poor general health [5, 6, 27–29]. We found that
taking crocin by the patients who were under MMT for
8 weeks improved depression, anxiety and general
health. Nowadays herbal medicine has attracted lots of
interest in the treatment of psychiatric problems such as
depression, anxiety and mental disorder. There are stud-
ies confirming the beneficial impacts of crocin adminis-
tration on depression, anxiety and general health in
individuals not undergoing MMT. In the study con-
ducted by Talaei et al. [12], crocin intake at a dosage of
30 mg/day for 4 weeks improved depression, anxiety,
general health and mood disorder in patients had been
diagnosed with MDD. In another study, administration
of saffron extract for 6 weeks to depressed patients
Fig. 1 Summary of patient flow
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helped with the treatment of mild to moderate depres-
sion [30]. Moreover, following saffron administration at
a dosage of 28 mg/day for 4 weeks, the median value of
anxiety and stress were significantly decreased in healthy
adults [15]. In addition, taking saffron at a dosage of 15
mg/Bid for 8 weeks by mothers suffering from mild-to-
moderate postpartum depressive disorder significantly
reduced depression and anxiety [31]. Also, in an animal
study conducted by Hosseinzadeh et al. [18], the petal
and stigma of saffron were introduced as antidepressant
in rat and mice models. All of these effects may be at-
tributed to a synergistic action of different constituents
in saffron such as crocin, picrocrocin, safranal and fla-
vonoids [12]. The accurate mechanism of action for
crocin in the brain and its impacts on depression and
anxiety parameters is not completely understood. Ad-
junctive therapy using crocin may provide powerful
antioxidant effects and prevent free radical induced
damage in the brain and subsequently improve mental
health status [32].
Effects on sleep quality
Sleep disorders are common among patients undergoing
MMT and the underlying reason may be due to drug
abuse related signs and other psychiatric co-morbidities
[33, 34]. Our study demonstrated that crocin administra-
tion to patients under MMT for 8 weeks significantly had
beneficial effects on their sleep quality. Little is known
about the effects of crocin on sleep quality in patients
under MMT. In a study conducted by Kell et al. [15], saf-
fron at dosages of 22mg/day and 28mg/day for 4 weeks
significantly improved the quality of sleep in healthy
adults. In another study, after saffron intake at a dosage of
300mg/day for 7 days there were beneficial effects in re-
ducing anxiety and improving the quality of sleep among
diabetic patients [35]. Also, in an animal study by Masaki
et al. [36], crocin increased the total time of non-REM
sleep in mice. Unlike, there are animal studies showing
that crocin administered intraperitoneal, did not affect
Table 1 General characteristics of the study participants1
Placebo group
(n = 25)
Crocin group
(n = 25)
P2
Age (y) 41.4 ± 8.8 40.1 ± 9.3 0.63
Height (cm) 171.2 ± 7.5 171.6 ± 8.4 0.84
Weight at study baseline (kg) 70.1 ± 8.5 68.9 ± 12.1 0.68
Weight at the end-of-trial (kg) 69.7 ± 8.6 69.0 ± 11.7 0.81
Weight change (kg) −0.4 ± 1.6 0.08 ± 1.4 0.23
BMI at study baseline (kg/m2) 23.9 ± 2.9 23.3 ± 3.6 0.51
BMI at the end-of-trial (kg/m2) 23.8 ± 3.0 23.4 ± 3.6 0.66
BMI change (kg/m2) −0.1 ± 0.5 0.05 ± 0.5 0.19
Education (%)
Illiterate 5 (20) 7 (28)
Elementary 5 (20) 7 (28)
Intermediate 12 (48) 10 (40) 0.58†
Diploma 2 (8) 0 (0)
High educated 1 (4) 1 (4)
Marital status (%)
Single 8 (32) 5 (20)
Married 5 (20) 8 (32) 0.50†
Widow/Divorced 12 (48) 12 (48)
Job (%)
Unemployed 16 (64) 18 (72)
Employed 2 (8) 1 (4) 0.76†
Others 7 (28) 6 (24)
Use of other drugs (%)
None 20 (80) 19 (76)
Benzodiazepine 2 (8) 3 (12) 0.89†
Antidepressants (SSRIs) 3 (12) 3 (12)
Methadone dose (mL/d) 19.2 ± 6.2 17.2 ± 5.9 0.25
Duration of MMT (y) 6.2 ± 2.6 5.5 ± 1.9 0.33
aData are mean ± SDs
bObtained from independent t-test
cObtained from Pearson Chi-square test
SSRIs selective serotonin reuptake inhibitors
Table 2 The effect of crocin on psychological parameters in methadone maintenance treatment patients
Variables Placebo group (n = 25) Crocin group (n = 25) Difference in outcome measures between crocin and placebo treatment groupsa
Baseline Week 8 Baseline Week 8 β (95% CI) Pb
BDI score 23.6 ± 6.6 24.7 ± 7.3 22.8 ± 5.4 17.6 ± 5.0 −6.66 (−9.88,-3.45) < 0.0001
BAI score 19.2 ± 4.0 19.2 ± 3.5 19.7 ± 6.6 15.3 ± 5.2 −4.35 (−5.94, −2.75) < 0.0001
GHQ score 35.6 ± 13.0 34.4 ± 12.23 34.8 ± 11.5 29.3 ± 10.2 −4.45 (−7.68, −1.22) 0.008
PSQI 6.7 ± 2.3 7.0 ± 2.6 6.4 ± 2.3 4.1 ± 1.8 −2.73 (−3.74, −1.73) < 0.0001
IIEF 22.0 ± 11.8 21.6 ± 12.1 21.0 ± 16.7 25.64 ± 16.5 4.98 (2.08, 7.88) 0.001
Data are mean ± SDs
a“Outcome measures” refers to the change in values of measures of interest between baseline and week 8. β [difference in the mean outcomes measures
between treatment groups (crocin group = 1 and placebo group = 0)]
bObtained from multiple regression model (adjusted for baseline age and BMI)
BDI Beck Depression Inventory, BAI Beck Anxiety Inventory, GHQ general health questionnaire, IIEF International Index of Erectile Functions, PSQI Pittsburgh Sleep
Quality Index
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hypnotic activity and anxiety [37]. The effects of saffron
on sleep quality are likely associated with the crocin and
safranol compounds of saffron [38]. Crocin and safranal
likely affect dopaminergic and serotonergic system and
nor-epinephrine reuptake inhibition [39]. Also, crocin
may modulate the histaminergic or cholinergic arousal
system [36]. Saffron has similar activity to hypnotic drugs.
Similar to diazepam as a benzodiazepine, it has anxiolytic,
analgesic, and sleeping effects [39].
Effects on sexual functions
Our findings showed that compared with the placebo;
taking crocin for 8 weeks by patients under MMT had
improved sexual functions. Previous studies have dem-
onstrated higher prevalence of sexual dysfunction among
patients undergoing Methadone Maintenance Treatment
(MMT) [8]. Several studies have evaluated the effects of
crocin intake on sexual functions in individuals not
undergoing MMT, though data on the effects of crocin
administration on sexual function in patients under
MMT are scarce. Saffron administration significantly im-
proves erectile dysfunction in diabetic patients [40]. In a
study conducted by Shamsa et al. [20], oral saffron ad-
ministration at a dose of 200 mg/day for 10 days im-
proved erectile function in males suffering from erectile
dysfunction [41]. In addition, taking saffron (15 mg
twice/day) for four weeks by married men with major
depressive disorder (MDD) suffering from fluoxetine-
related sexual dysfunction had promising effects on sex-
ual dysfunction with acceptable patient’s tolerance [42].
Also, in an animal study by Hosseinzadeh et al. [43], ad-
ministered safranal, crocin, and sildenafil to normal male
rats increased sexual desire and frequency of erection in
groups receiving Sildenafil and crocin. However, our
findings were inconsistent with the results from previous
studies on treating erectile dysfunction in men naïve to
treatment [44]. This inconsistency may be attributed to
the quality of saffron and its cultivation site, the dosage
used, and the formula used for the prepared medication.
Saffron appears to interact with several neurotransmitter
systems [45–47]. Moreover, nitric oxide and opioid sys-
tem play important roles in sexual function, and saffron
seems to interact with both of them [48–50]. Whether
the underlying mechanisms of these effects lead to the
beneficial sexual effects of saffron certainly requires add-
itional studies [17, 51, 52].
Limitations
The present study had some limitations. The duration of
intervention was short. Long-term interventions might
Fig. 2 Change (means± SDs) in BDI score, BAI score and GHQ score in patients under MMT who were candidate for receiving crocin
supplements and placebo. P value was obtained from independent t-test. N = 25 in each group
Fig. 3 Change (means± SDs) in PSQI score and IIEF score in patients under MMT who were candidate for receiving crocin supplements and
placebo. P value was obtained from independent t-test. N = 25 in each group. BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; GHQ,
general health questionnaire; IIEF, International Index of Erectile Functions; MMT, methadone maintenance treatment; PSQI, Pittsburgh Sleep
Quality Index
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lead to better effects on psychological parameters. In
addition, we did not evaluate the effects of crocin on
biomarkers of inflammation, oxidative stress, and its re-
lated gene expression. Also, we could not investigate the
pain in patients under MMT. Therefore, investigation of
pain caused by quitting is suggested in future studies.
Conclusions
Overall, taking crocin by patients under MMT had benefi-
cial effects on depression, anxiety, general health, sleep
quality and sexual functions. Crocin can be recommended
as an adjunct to methadone in opioid withdrawal proto-
cols which improves quality of life and diminishes opioids
side effects.
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